PharmiWeb.com - Global Pharma News & Resources
02-Jul-2019

Duloxetine API Market to Hit USD 3,985.0 Mn by 2023 | CAGR 3.52%

The Global Duloxetine API Market is anticipated to register a growth rate of CAGR 3.52% and is expected to reach the value of USD 3,985.0 million by the year 2023

Duloxetine API Market Information: by Application (Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain), by Region (Americas, Europe, Asia-Pacific, Others)mdash;Forecast till 2023

We can provide sample pages for a better understanding of this report.
Request Sample of This Report @http://www.amecoresearch.com/sample/14028

Market analysis

Active pharmaceutical ingredients (APIs) are utilized in the assembling of pharmaceutical definitions. Duloxetine is a serotonin-norepinephrine reuptake inhibitor utilized in the treatment of discouragement and uneasiness. In addition, it is utilized to help mitigate neuropathic torment in individuals with diabetes or progressing torment because of ailments, for example, joint inflammation, unending back pain, or fibromyalgia. The developing predominance of misery, expanding entrance of conventional medications, expanding instances of nervousness, the developing pattern of outsourcing, strong drug pipeline, and developing interest for recently grown little particle medications are foreseen to support the market development over the forecast time frame. Be that as it may, the components, for example, changing monetary conditions in various areas and symptoms of duloxetine may frustrate the market development over the gauge time frame. The global duloxetine API market is anticipated to register a growth rate of CAGR 3.52% and is expected to reach the value of USD 3,985.0 million by the year 2023.

Market segmentation

The global duloxetine API market has been segmented on the basis of its application and regional demand. Based on its application, the market has been categorized into a generalized anxiety disorder, major depressive disorder, fibromyalgia, chronic musculoskeletal pain, neuropathic pain, and others.

Regional demand

Geographically, the global duloxetine API market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Shodhana Laboratories (India), Hetero (India), Apotex Inc. (Canada), Shionogi Inc. (US), and Zhejiang Huahai Pharmaceutical Co., Ltd (China), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States), among others are some of the major players in the global duloxetine API market.

View Detail Report With Complete Table Of Content@ http://www.amecoresearch.com/market/global-duloxetine-api-market-mrfr-14028

Table Of Contents

Global Duloxetine API Market Research Report Forecast to 2023

1 Executive Summary
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Overview
4.2 Drivers
4.2.1 Rising Rates of Anxiety Cases
4.2.2 Increasing Prevalence Rates of Depression
4.2.3 Increasing Penetration of Generic Versions of Drugs
4.2.4 Strong Drug Pipeline
4.2.5 Growing Demand for Newly Developed Small Molecule Drugs
4.2.6 Growing Trend of Outsourcing
4.3 Restraints
4.3.1 Changing Economic Conditions in Different Regions
4.3.2 Side-Effects of Duloxetine
4.4 Opportunities
4.4.1 Advancements in API Manufacturing
4.4.2 Patent Expiry Creating Opportunities for Generic and API Manufacturers
5 Market Factor Analysis
5.1 Supply Chain Analysis
5.1.1 Overview
5.1.2 Ramp;D
5.1.3 Procurement of Raw Material
5.1.4 Manufacturing
5.1.5 Distributor
5.1.6 End User
5.2 Porterrsquo;s Five Forces Model
5.2.1 Overview
5.2.2 Threat of New Entrants
5.2.3 Bargaining Power of Suppliers
5.2.4 Threat of Substitutes
5.2.5 Bargaining Power of Buyers
5.2.6 Intensity of Rivalry
5.3 Manufacturing Process for API
5.4 Synthesis of Duloxetine Hydrochloride
5.4.1 General Process for Synthesis of Duloxetine Hydrochloride
5.4.2 Variation in the Process According to Different Patents
5.5 Regulatory Scenario
5.5.1 Overview
5.6 Registration of API in the US
5.6.1 US Drug Master File (DMF)
5.7 Registration of API in the European Union (EU)
5.7.1 Active Substance Master File (ASMF)
5.8 Comparison of requirements for the registration of API in the US and the EU
5.9 Registration of Duloxetine API
5.1 Specifications
5.11 Pricing Evolution
5.12 Patent Analysis
5.12.1 Overview
5.12.2 Patent Analysis for Duloxetine Drug
5.13 Patent Analysis for the Preparation of Duloxetine Hydrochloride
5.13.1 Methods for the Preparation of Duloxetine Hydrochloride
5.13.2 Process for the Preparation of Duloxetine Hydrochloride
5.13.3 Method for the Preparation of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine
Hydrochloride (duloxetine) 35
5.13.4 Process for the Preparation of Duloxetine Hydrochloride
5.13.5 Synthesis and Preparations of Duloxetine Salts
5.13.6 Preparation of Chemically and Enantiomerically Pure Duloxetine HCl
5.13.7 Antidepressant Oral Liquid Compositions
5.14 Duloxetine Hydrochloride Delayed-Release Formulations
5.14.1 Preparation of Duloxetine Hydrochloride Using Optically Active Methylhydroxylaminopropanol Compound as an Intermediate
5.14.2 Process for the Preparation of Duloxetine Hydrochloride
5.14.3 Process for Pure Duloxetine Hydrochloride
5.14.4 Process for the Preparation of Pure Duloxetine Hydrochloride
5.14.5 Process for the Preparation of Duloxetine Hydrochloride and its Precursors
5.15 Product Pipeline Analysis
5.15.1 Overview
5.15.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS
5.15.3 Effect of Combined Morphine and Duloxetine on Chronic Pain
5.15.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain
5.15.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder
5.15.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy
6 Global Duloxetine API Market by Application
6.1 Overview
6.2 Major Depressive Disorder
6.3 Generalized Anxiety Disorder (GAD)
6.4 Fibromyalgia
6.5 Neuropathic Pain
6.6 Chronic Musculoskeletal Pain
6.7 Others
7 Global Duloxetine API Market by Region
7.1 Overview
7.2 Americas
7.2.1 North America
7.2.1.1 US
7.2.1.2 Canada
7.2.2 Latin America
7.3 Europe
7.3.1 Western Europe
7.3.1.1 Germany
7.3.1.2 France
7.3.1.3 UK
7.3.1.4 Italy
7.3.1.5 Spain
7.3.1.6 Rest of Western Europe
7.3.2 Eastern Europe
7.4 Asia-Pacific
7.4.1 China
7.4.2 India
7.4.3 Japan
7.4.4 Rest of Asia-Pacific
7.5 Middle East amp; Africa
7.5.1 Middle East
7.5.2 Africa
8 Competitive Landscape
8.1 Introduction
8.2 Company Ranking
8.3 Key Customers
9 Company Profiles
9.1 Teva Pharmaceutical Industries Ltd
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Products/Services Offered
9.1.4 Key Developments
9.1.5 SWOT Analysis
9.1.6 Key Strategies
9.2 Sun Pharmaceutical Industries Ltd
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Products/Services Offered
9.2.4 Key Developments
9.2.5 SWOT Analysis
9.2.6 Key Strategies
9.3 Aurobindo Pharma
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Products/Services Offered
9.3.4 Key Developments
9.3.5 SWOT Analysis
9.3.6 Key Strategies
9.4 Lupin
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Products/Services Offered
9.4.4 Key Developments
9.4.5 SWOT Analysis
9.4.6 Key Strategies
9.5 Zydus Cadila
9.5.1 Company Overview
9.5.2 Financial Overview
9.5.3 Products/Services Offered
9.5.4 Key Developments
9.5.5 SWOT Analysis
9.5.6 Key Strategies
9.6 Eli Lilly and Company
9.6.1 Company Overview
9.6.2 Financial Overview
9.6.3 Products Offering
9.6.4 Key Developments
9.6.5 SWOT Analysis
9.6.6 Key Strategies
9.7 Shodhana Laboratories
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Products/Services Offered
9.7.4 Key Developments
9.7.5 SWOT Analysis
9.7.6 Key Strategies
9.8 Hetero
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Products/Services Offered
9.8.4 Key Developments
9.8.5 SWOT Analysis
9.8.6 Key Strategies
9.9 Apotex Inc.
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Products/Services Offered
9.9.4 Key Developments
9.9.5 SWOT Analysis
9.9.6 Key Strategies
9.1 Shionogi Inc.
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Products/Services Offered
9.10.4 Key Developments
9.10.5 SWOT Analysis
9.10.6 Key Strategies
9.11 Zhejiang Huahai Pharmaceutical Co., Ltd
9.11.1 Company Overview
9.11.2 Financial Overview
9.11.3 Products/Services Offered
9.11.4 Key Developments
9.11.5 SWOT Analysis
9.11.6 Key Strategies
10 Appendix
10.1 References
10.2 Related Reports

Quick Buy This Premium Report From Here: http://www.amecoresearch.com/buy/14028

About Us:

Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact:

Email: sales@amecoresearch.com | +1 407 915 4157

Editor Details

Last Updated: 02-Jul-2019